Logo image of BJDX

BLUEJAY DIAGNOSTICS INC (BJDX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BJDX - US0956335097 - Common Stock

0.966 USD
-0.05 (-5.29%)
Last: 12/16/2025, 10:16:39 AM
Fundamental Rating

2

BJDX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. BJDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BJDX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BJDX has reported negative net income.
BJDX had a negative operating cash flow in the past year.
BJDX had negative earnings in each of the past 5 years.
BJDX had a negative operating cash flow in each of the past 5 years.
BJDX Yearly Net Income VS EBIT VS OCF VS FCFBJDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

With a Return On Assets value of -410.48%, BJDX is not doing good in the industry: 96.79% of the companies in the same industry are doing better.
BJDX has a worse Return On Equity (-543.59%) than 82.89% of its industry peers.
Industry RankSector Rank
ROA -410.48%
ROE -543.59%
ROIC N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BJDX Yearly ROA, ROE, ROICBJDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BJDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BJDX Yearly Profit, Operating, Gross MarginsBJDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for BJDX has been increased compared to 1 year ago.
BJDX has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BJDX has an improved debt to assets ratio.
BJDX Yearly Shares OutstandingBJDX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M
BJDX Yearly Total Debt VS Total AssetsBJDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -14.72, we must say that BJDX is in the distress zone and has some risk of bankruptcy.
BJDX has a Altman-Z score of -14.72. This is amonst the worse of the industry: BJDX underperforms 84.49% of its industry peers.
BJDX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, BJDX is in the better half of the industry, outperforming 73.80% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -14.72
ROIC/WACCN/A
WACCN/A
BJDX Yearly LT Debt VS Equity VS FCFBJDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M 20M

2.3 Liquidity

A Current Ratio of 2.92 indicates that BJDX has no problem at all paying its short term obligations.
With a Current ratio value of 2.92, BJDX perfoms like the industry average, outperforming 56.15% of the companies in the same industry.
BJDX has a Quick Ratio of 2.92. This indicates that BJDX is financially healthy and has no problem in meeting its short term obligations.
BJDX's Quick ratio of 2.92 is fine compared to the rest of the industry. BJDX outperforms 64.71% of its industry peers.
Industry RankSector Rank
Current Ratio 2.92
Quick Ratio 2.92
BJDX Yearly Current Assets VS Current LiabilitesBJDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

BJDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.60%, which is quite impressive.
EPS 1Y (TTM)97.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 30.65% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BJDX Yearly Revenue VS EstimatesBJDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2025 2026 2M 4M 6M 8M
BJDX Yearly EPS VS EstimatesBJDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -500 -1K -1.5K -2K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BJDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BJDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BJDX Price Earnings VS Forward Price EarningsBJDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BJDX Per share dataBJDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

BJDX's earnings are expected to grow with 30.65% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.65%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BJDX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BLUEJAY DIAGNOSTICS INC

NASDAQ:BJDX (12/16/2025, 10:16:39 AM)

0.966

-0.05 (-5.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-28 2024-03-28/amc
Earnings (Next)N/A N/A
Inst Owners5.94%
Inst Owner Change-5.19%
Ins Owners0.03%
Ins Owner Change0%
Market Cap1.75M
Revenue(TTM)N/A
Net Income(TTM)-20.07M
Analysts43.33
Price TargetN/A
Short Float %1.68%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-33.6
EYN/A
EPS(NY)-0.3
Fwd EYN/A
FCF(TTM)-3.5
FCFYN/A
OCF(TTM)-3.5
OCFYN/A
SpS0
BVpS2.04
TBVpS2.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -410.48%
ROE -543.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-195.93%
ROA(5y)-136.14%
ROE(3y)-263.31%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -2.81%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.92
Quick Ratio 2.92
Altman-Z -14.72
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)421.46%
Cap/Depr(5y)255.54%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.91%
EPS Next Y67.68%
EPS Next 2Y30.65%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.27%
OCF growth 3YN/A
OCF growth 5YN/A

BLUEJAY DIAGNOSTICS INC / BJDX FAQ

What is the ChartMill fundamental rating of BLUEJAY DIAGNOSTICS INC (BJDX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to BJDX.


What is the valuation status for BJDX stock?

ChartMill assigns a valuation rating of 1 / 10 to BLUEJAY DIAGNOSTICS INC (BJDX). This can be considered as Overvalued.


How profitable is BLUEJAY DIAGNOSTICS INC (BJDX) stock?

BLUEJAY DIAGNOSTICS INC (BJDX) has a profitability rating of 0 / 10.


How financially healthy is BLUEJAY DIAGNOSTICS INC?

The financial health rating of BLUEJAY DIAGNOSTICS INC (BJDX) is 4 / 10.


What is the earnings growth outlook for BLUEJAY DIAGNOSTICS INC?

The Earnings per Share (EPS) of BLUEJAY DIAGNOSTICS INC (BJDX) is expected to grow by 67.68% in the next year.